GC1008 (fresolimumab), a human anti-TGF−β monoclonal antibody, has been tested in patients with advanced malignant melanoma, renal cell carcinoma, and diabetic nephropathy and demonstrated acceptable safety and preliminary evidence of antitumor activity (37, 38). This evidence concerns the gene TGFB1 and hereditary clear cell renal cell carcinoma.